TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
Name: adagloxad simolenin/OBI-821Description: Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21. Adagloxad simolenin will be mixed with OBI-821 before administration.Type: Biological
adagloxad simolenin arm
Name: TACEDescription: Transarterial chemoembolizationType: Procedure
TACE alone arm adagloxad simolenin arm
Description: time-to-intrahepatic total tumor volume progressionMeasure: time-to-ITTVP Time: From enrollment till 36 months of follow-up.
There is one SNP
5. Child-Pugh functional class A or B. 6. GALNT14- rs9679162 "non TT" genotype 7.